DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has launched Soltamox® (tamoxifen citrate) oral solution in the United States. Soltamox is a new treatment option for breast cancer patients who are prescribed tamoxifen therapy. DARA has exclusive U.S. rights to Soltamox from Rosemont Pharmaceuticals, Ltd, UK.
Since its approval in 1977, tamoxifen has been used to treat millions of women and men diagnosed with hormone-receptor-positive breast cancer. Treatment with tamoxifen lowers the risk of breast cancer recurrence, breast cancer in the opposite breast, and death from breast cancer.
Breast cancer remains a serious medical issue with over 2.6 million patients in the U.S. with a history of the disease and an estimated 240,000 new patients diagnosed each year. Breast cancer is the leading cause of cancer death in women between the ages of 15 and 54, and the second-leading cause of cancer death in women 55 to 74.
Helping patients who may have difficulty swallowing pillsPrior to DARA's launch of Soltamox, tamoxifen was only available in the U.S. as a solid oral tablet. Difficulty swallowing pills is not uncommon and certain breast cancer patients may experience such difficulties as a result of surgical, pharmaceutical, radiation, or chemotherapy treatments. Discomfort or problems when swallowing may lead patients to miss doses or discontinue their treatment. Soltamox provides an oral liquid medication option that may provide an opportunity for patients to remain compliant with prescribed tamoxifen therapy. DARA CEO, David J. Drutz, MD, stated, “Compliance and adherence to prescribed tamoxifen therapy is a critical issue in patient care and may affect treatment outcomes. Soltamox provides a unique treatment option for those patients with swallowing difficulties or who simply prefer an oral liquid over tablets or pills. We are excited to provide breast cancer patients an alternative to their current tamoxifen formulation that may help them achieve long-term treatment success.” Dr. Drutz added, "The launch of Soltamox represents a major milestone for DARA in our quest to become a premier provider of important oncology treatment and supportive care products."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV